Effect of Dupilumab in CRSwNP Sinonasal Outcomes from Real Life Studies: A Systematic Review with Meta-analysis.

IF 5.4 2区医学 Q1 ALLERGY

Current Allergy and Asthma Reports Pub Date : 2025-02-05 DOI:10.1007/s11882-025-01192-y

Miguel Rodriguez-Iglesias, Christian Calvo-Henríquez, Daniel Martin-Jimenez, Ainhoa García-Lliberós, Juan Maza-Solano, Ramon Moreno-Luna, Adriana Izquierdo-Domínguez, Gabriel Martínez-Capoccioni, Isam Alobid

{"title":"Effect of Dupilumab in CRSwNP Sinonasal Outcomes from Real Life Studies: A Systematic Review with Meta-analysis.","authors":"Miguel Rodriguez-Iglesias, Christian Calvo-Henríquez, Daniel Martin-Jimenez, Ainhoa García-Lliberós, Juan Maza-Solano, Ramon Moreno-Luna, Adriana Izquierdo-Domínguez, Gabriel Martínez-Capoccioni, Isam Alobid","doi":"10.1007/s11882-025-01192-y","DOIUrl":null,"url":null,"abstract":"Purpose of review: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a debilitating inflammatory condition that significantly impacts quality of life. Despite treatment advances, recurrence is common, prompting the exploration of novel therapies such as monoclonal antibodies targeting the type 2 immune response, notably dupilumab. This research aims to evaluate the real-world evidence (RWE) of dupilumab in treating severe CRSwNP, comparing sinonasal outcomes to those observed in randomized clinical trials.Recent findings: Significant improvements were noted, with the average SNOT-22 score reduction being 37.2 points post-dupilumab treatment. The nasal polyp size (NPS) showed an average decrease of 3.6 points. The analysis highlighted the practical effectiveness of dupilumab, emphasizing its benefit over conventional therapies in reducing NPS and improving nasal symptoms. The findings advocate for the integration of dupilumab into standard treatment protocols for severe CRSwNP, providing a robust alternative that could potentially reduce the high recurrence rates associated with current management strategies. This study underscores the utility of RWE in assessing the effectiveness of new medical treatments, suggesting that dupilumab offers substantial real-world benefits for patients suffering from this challenging condition.","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":"25 1","pages":"13"},"PeriodicalIF":5.4000,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11799128/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Allergy and Asthma Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11882-025-01192-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a debilitating inflammatory condition that significantly impacts quality of life. Despite treatment advances, recurrence is common, prompting the exploration of novel therapies such as monoclonal antibodies targeting the type 2 immune response, notably dupilumab. This research aims to evaluate the real-world evidence (RWE) of dupilumab in treating severe CRSwNP, comparing sinonasal outcomes to those observed in randomized clinical trials.

Recent findings: Significant improvements were noted, with the average SNOT-22 score reduction being 37.2 points post-dupilumab treatment. The nasal polyp size (NPS) showed an average decrease of 3.6 points. The analysis highlighted the practical effectiveness of dupilumab, emphasizing its benefit over conventional therapies in reducing NPS and improving nasal symptoms. The findings advocate for the integration of dupilumab into standard treatment protocols for severe CRSwNP, providing a robust alternative that could potentially reduce the high recurrence rates associated with current management strategies. This study underscores the utility of RWE in assessing the effectiveness of new medical treatments, suggesting that dupilumab offers substantial real-world benefits for patients suffering from this challenging condition.

查看原文本刊更多论文

Dupilumab对CRSwNP鼻窦预后的影响：一项系统综述和荟萃分析。

综述目的：慢性鼻窦炎伴鼻息肉（CRSwNP）是一种衰弱性炎症，显著影响生活质量。尽管治疗取得了进展，但复发是常见的，这促使人们探索新的治疗方法，如针对2型免疫反应的单克隆抗体，特别是dupilumab。本研究旨在评估dupilumab治疗严重CRSwNP的真实证据（RWE），将鼻窦结局与随机临床试验中观察到的结果进行比较。最近的发现：显著的改善被注意到，dupilumab治疗后，SNOT-22评分平均降低37.2分。鼻息肉大小（NPS）平均下降3.6分。该分析强调了dupilumab的实际有效性，强调其在减少NPS和改善鼻症状方面优于传统疗法。研究结果提倡将dupilumab整合到严重CRSwNP的标准治疗方案中，提供了一个强有力的替代方案，可以潜在地降低与当前管理策略相关的高复发率。这项研究强调了RWE在评估新医学治疗有效性方面的效用，表明dupilumab为患有这种具有挑战性的疾病的患者提供了实质性的现实益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Allergy and Asthma Reports 医学-过敏

CiteScore

11.20

自引率

1.80%

发文量

审稿时长

6-12 weeks

期刊介绍： The aim of Current Allergy and Asthma Reports is to systematically provide the views of highly selected experts on current advances in the fields of allergy and asthma and highlight the most important papers recently published. All reviews are intended to facilitate the understanding of new advances in science for better diagnosis, treatment, and prevention of allergy and asthma. We accomplish this aim by appointing international experts in major subject areas across the discipline to review select topics emphasizing recent developments and highlighting important new papers and emerging concepts. We also provide commentaries from well-known figures in the field, and an Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research. Over a one- to two-year period, readers are updated on all the major advances in allergy and asthma.